Patients with stage II of the knee osteoarthritis most likely benefit from the intra-articular injections of autologous adipose tissue—from 2 years of follow-up studies
Paweł Bąkowski,Jakub Kaszyński,Cezary Baka,Tomasz Kaczmarek,Kinga Ciemniewska-Gorzela,Kamilla Bąkowska-Żywicka,Tomasz Piontek +6 more
TLDR
In this paper, the authors defined a specific group of patients with knee osteoarthritis, who are the most likely to benefit from the treatment with intra-articular injection of an autologous adipose tissue (AAT).Abstract:
Knee osteoarthritis (OA) is a common, chronic, progressive and degenerative disease which affects patients’ quality of life and may cause disability and social isolation. OA is a huge economic burden for the patient and a large strain for the whole healthcare system. Articular cartilage has a small potential to repair, with progressively more clinicians emphasizing cellular therapy. Subcutaneous fat tissue in human body is a large reservoir of mesenchymal stem cells (MSCs) and is been harvested in minimally invasive, simple procedure. The purpose of this study was to define a specific group of patients with knee osteoarthritis, who are the most likely to benefit from the treatment with intra-articular injection of an autologous adipose tissue (AAT). From 2016 to 2018, 59 symptomatic bilateral and unilateral knee OA patients were treated with a single intra-articular (IA) injection of an autologous adipose tissue (AAT). Before the treatment and at the follow-up, the participant was asked to fulfill the Knee Injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee 2000 (IKDC 2000), The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Health Questionnaire EQ-5D-5L and to quantify the pain in the affected joint with a Numeric Rating Scale (NRS). Moreover, the patients were asked to: (i) assess their satisfaction with the effects of the conducted treatment: from 0 (unsatisfied) to 10 (very satisfied), (ii) describe the rehabilitation, if it was performed (supervised or individual and duration in weeks) and (iii) indicate any additional treatment applied, like IA injections of hyaluronic acid (HA) or platelet-rich plasma (PRP), knee arthroscopy, partial or total knee arthroplasty (TKA) at the follow-up. The mean age of 37 participants (16 males and 21 females) included into statistical analysis was 57.78 ± 7.39 years, the mean BMI was 31.30 ± 7.51. The questionnaires were fulfilled after the average follow-up time of 27 ± 6.5 months. A significant difference (p < 0.05) compared with the baseline, was observed in pain [NRS], WOMAC, KOOS index, pain, symptoms, ADL, Sport and Rec, QoL, EQ-5D-5L index. The satisfaction in the whole group was 6.16 ± 3.07. There was no significant difference between satisfied and unsatisfied patients in BMI and pain [NRS] at the baseline. 6 out of 7 patients with stage IV in K-L were unsatisfied with the effects of the treatment with AAT. The main conclusion of this study is that the patients with stage II of the knee OA with normal BMI are were most likely to benefit from IA injection of AAT, in contrast to the patients with stage IV, who will not beware not satisfied with the effectiveness of this kind of treatment. There were no adverse events reported at the donor site as well as in the treated knee joints.read more
Citations
More filters
Journal ArticleDOI
Methodological Flaws in Meta-Analyses of Clinical Studies on the Management of Knee Osteoarthritis with Stem Cells: A Systematic Review
Christoph Dipl.-Ing. Schmitz,Christopher Alt,David A. Pearce,John P. Furia,Nicola Maffulli,Eckhard Alt +5 more
TL;DR: Clinicians should interpret the results of the 19 assessed meta-analyses of clinical studies on the management of primary knee osteoarthritis with stem cells with caution and should be cautious of the conclusions drawn therein.
Journal ArticleDOI
Non-homologous use of adipose-derived cell and tissue therapies: Osteoarthritis as a case study
Trivia Frazier,Keith L. March,Jaime R. Garza,Bruce A. Bunnell,K. Darr,Emma Rogers,Katie Hamel,Jeffrey M. Gimble +7 more
TL;DR: In this paper , a review of the regulatory landscape governing the utilization of autologous and allogeneic adipose tissue remains complex, and the FDA's nomenclature and guidance regarding adipose products are discussed.
Journal ArticleDOI
Intra-articular injection of stromal vascular fraction for knee degenerative joint disease: a concise review of preclinical and clinical evidence
TL;DR: The meta-analysis of clinical research shows that intra-articular injection of SVF, in combination with adjuvant surgery, could alleviate pain and improve early functional recovery for patients with KDJD at Kellgren-Lawrence (KL) grades II–III.
Journal ArticleDOI
Infiltration therapy in the context of cartilage surgery.
TL;DR: The role of a combination therapy with use of intra-articular corticosteroids is lacking in the absence of adequate study data and cannot be defined yet as discussed by the authors , however, the current scientific data do not yet justify any recommendation for its use.
References
More filters
Journal ArticleDOI
Current Treatment Options for Osteoarthritis
TL;DR: Current evidence from the available studies does not support the use of TNF-alpha blockers in OA, and new therapies for OA are awaited both as a safe symptomatic treatment - alternative to the conventional treatment options and as a disease-modifying therapy that would revolutionize the contemporary approach to OA.
Journal ArticleDOI
Diagnosis and treatment of osteoarthritis.
TL;DR: Osteoarthritis presents in primary and secondary forms, and the most common symptom is pain.
Journal ArticleDOI
The role of muscle strengthening in exercise therapy for knee osteoarthritis: A systematic review and meta-regression analysis of randomized trials
Cecilie Bartholdy,Carsten Bogh Juhl,Robin Christensen,Hans Lund,Weiya Zhang,Marius Henriksen +5 more
TL;DR: Exercise interventions following the ACSM criteria for strength training provide superior outcomes in knee extensor strength but not in pain or disability, according to the meta-regressions.
Journal ArticleDOI
Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation.
Jaskarndip Chahal,Alejandro Gómez-Aristizábal,K. Shestopaloff,S. Bhatt,A. Chaboureau,Antonietta Fazio,Jolene Chisholm,Amanda Weston,Julia Chiovitti,Armand Keating,Mohit Kapoor,Darrell Ogilvie-Harris,Khalid Syed,Rajiv Gandhi,Nizar N. Mahomed,Kenneth W. Marshall,Marshall S. Sussman,Ali Naraghi,Sowmya Viswanathan +18 more
TL;DR: Analytical tools provide important insights into BM‐ MSC dosing and BM‐MSC reduction of synovial inflammation and cartilage degradation and provide a highly predictive donor selection criterion that will be critical in translating MSC therapy for osteoarthritis.
Journal ArticleDOI
MSCs: The Sentinel and Safe-Guards of Injury
TL;DR: Key to this new understanding is that MSCs are not “stem cells,” but rather as Medicinal Signaling Cells as the therapeutic agents.